Trinity Legacy Partners LLC Sells 358 Shares of Johnson & Johnson (NYSE:JNJ)

Trinity Legacy Partners LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,496 shares of the company’s stock after selling 358 shares during the period. Johnson & Johnson comprises 2.1% of Trinity Legacy Partners LLC’s portfolio, making the stock its 11th largest holding. Trinity Legacy Partners LLC’s holdings in Johnson & Johnson were worth $5,439,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Family CFO Inc purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $26,000. RE Dickinson Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after acquiring an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its position in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after acquiring an additional 120 shares during the last quarter. Professional Financial Advisors LLC boosted its position in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after acquiring an additional 68 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC bought a new position in shares of Johnson & Johnson during the first quarter worth $38,000. Institutional investors own 68.59% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. SVB Leerink lowered their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Citigroup cut their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. UBS Group cut their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $166.18 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a 50 day simple moving average of $168.06 and a two-hundred day simple moving average of $174.12. The stock has a market cap of $436.92 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.95 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same period in the previous year, the business posted $2.48 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.72%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Johnson & Johnson announced that its Board of Directors has approved a stock repurchase program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.